Background: Less than 1% of all adult malignancies and 12% of pediatric cancers are sarcomas, an uncommon and diverse category of mesenchymal malignant tumors. The histologic subtype of soft tissue sarcoma (STS), in addition to the tumors, location, and grade, is a key prognostic factor currently, among the most popular therapies for STSs include surgery, radiation, and chemotherapy. Objective: The goal of this paper is to determine soft tissue sarcoma's epidemiology and prognostic markers retrospectively. It also shows the outcomes for overall survival (OS) and event-free survival (EFS) among Egyptian patients treated at the clinical oncology and nuclear medicine department of Zagazig University and Ahmad Maher Teaching hospitals. Patient and Methods: We reviewed retrospectively clinical features and tumor characteristics of the medical record of 121 patients with soft tissue sarcoma presented to Ahmed Maher teaching hospital and clinical oncology and Nuclear Medicine Department of Zagazig University in the period from January 2010 to December 2021 received chemotherapy or chemoradiotherapy, the study group's demographic information included sex, age, follow-up time, and gender, the main tumor site, size, histological subtype, grade, clinical group, and risk stratification were reviewed as tumor features, to assess the degree of tumor resection or elimination, surgical reports, pathology reports, and tumor response to treatment. Conclusion: Overall survival (OS) is better in extremities than retroperitoneal sarcoma, local recurrence-free survival (LRFS) was better in extremities and visceral sarcoma, disease-free survival (DFS) was better in extremities than retroperitoneal which was better than visceral sarcoma and progression-free survival (PFS) was better in extremities than visceral sarcoma.